Liver transplantation for an infant with neonatal intrahepatic cholestasis caused by citrin deficiency using heterozygote living donor |
| |
Authors: | Takanobu Shigeta Mureo Kasahara Takuya Kimura Akinari Fukuda Kazunari Sasaki Katsuhiro Arai Atsuko Nakagawa Satoshi Nakagawa Keiko Kobayashi Shun Soneda Hiroaki Kitagawa |
| |
Affiliation: | 1. Departments of Transplant Surgery;2. Gastroenterology;3. Pathology;4. Intensive Care Unit, National Center for Child Health and Development, Tokyo, Japan;5. Department of Molecular Metabolism and Biochemical Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan;6. Departments of Pediatrics;7. Pediatric Surgery, St. Marianna School of Medicine Hospital, Kanagawa, Japan |
| |
Abstract: | Shigeta T, Kasahara M, Kimura T, Fukuda A, Sasaki K, Arai K, Nakagawa A, Nakagawa S, Kobayashi K, Soneda S, Kitagawa H. Liver transplantation for an infant with neonatal intrahepatic cholestasis caused by citrin deficiency using heterozygote living donor. Pediatr Transplantation 2010: 14:E86–E88. © 2009 John Wiley Sons & A/S. Abstract: NICCD is an autosomal recessive genetic disorder, characterized by cholestasis, coagulopathy, hypoglycemia, fatty liver and multiple amino acidemia. NICCD develops in the neonatal/infantile period and has been reported as a “naturally curable” disease within one yr of life. Recently, we experienced an infantile NICCD who developed progressive liver failure, and required subsequent LT using a heterozygote living donor at eight months of age. Diagnosis of NICCD was established before transplantation, and donor evaluation included mutation in the SLC25A13 gene for exclusion of individuals with citrin deficiency citrullinemia. LDLT, from blood type identical mother using a left lateral segment graft, was performed without serious complication. Plasma amino acid concentration was normalized rapidly, and the patient was discharged 30 days after transplant. During one yr follow up, the recipient has been doing well without additional medication for NICCD. NICCD should be considered in the differential diagnosis as a cause of neonatal/infantile cholestatic disease. LT using a heterozygote living donor is an effective alternative in countries where a deceased donor is not available. |
| |
Keywords: | neonatal intrahepatic cholestasis caused by citrin deficiency living donor liver transplantation adult‐onset type II citrullinemia heterozygote donor end‐stage liver disease |
|
|